The National Comprehensive Cancer Network recently updated their patient guide to support stereotactic body radiation therapy (SBRT) for prostate cancer.
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 26 of the world’s leading cancer centers, is dedicated to improving the quality, efficiency, and effectiveness of care for patients with cancer.
NCCN aims to provide people with cancer and the general public with state-of-the-art cancer treatment information in easy-to-understand language. The NCCN Guidelines for Patients®, translations of the NCCN clinical guidelines, are meant to help patients with cancer talk with their physicians about the best treatment options for their disease.
The NCCN guidelines for patients now states “Stereotactic body radiotherapy (SBRT, for short) has been added as an option to be carefully decided. If chosen, it should be received at cancer centers with the proper equipment and experience.”
At Philadelphia CyberKnife, our physician team and staff have extensive experience treating patients with stereotactic radiation therapy. Prostate cancer patients are treated with SBRT using the CyberKnife® Robotic Radiosurgery System. CyberKnife is a powerful, noninvasive treatment system that precisely focuses radiation to match the size and shape of a patient’s prostate cancer, minimizing damage to surrounding tissue.
For more information on NCCN’s Guidelines for Patients, please click here. To learn more about the benefits of CyberKnife treatment, or to find out if you are a candidate, click here.